EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 3.0

Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis

G P Borja-Cabrera, F B Santos, E Picillo, A E Gravino, L Manna, C B Palatnik-de-Sousa

Procedia in Vaccinology · 2009

DOI: 10.1016/j.provac.2009.07.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Procedia in Vaccinology, 2009. Verfasst von G P Borja-Cabrera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inst. de Microbiologia Prof. Paulo de Góes., Avenida Carlos Chagas Filho, 373, Cidade Universitária. Ilha do Fundão.Universidade Federal do Rio de Ja…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Nucleoside Hydrolase (NH36) is the main marker of the FML complex of Leishmania donovani, antigen of the licensed Leishmune® vaccine for prophylaxis of canine visceral leishmaniasis. As a DNA vaccine in mice, it induces a TH1 immune response. We vaccinated mongrel dogs with the VR1012NH36 vaccine for prophylaxis and immunotherapy against a high dose Leishmania chagasi infection (7 x 108 infective amastigotes). The untreated controls developed more symptoms, higher parasite/lymphocyte ratio, smaller DTH reactions, lower proportions of NH36-specific CD4+ cells and sustained NH36-specific CD8+ cell counts than dogs of the prophylaxis group. In the immunotherapy treated group, enlarged DTH reactions, enhanced CD4+ and sustained CD8+ lymphocyte proportions were also detected, however, without reduction of symptoms or parasite/lymphocyte ratio, indicating that the vaccine was sufficiently potent to prevent but not to control the disease. Both treatments determined higher survival rates. Anti-FML antibodies increased in vaccinated and control dogs while anti-NH36 antibodies were only increased in vaccinees (p= 0.000). The parasite load of an untreated survivor control dog (638.05 parasites) felt outside the IC95% of that of vaccinated dogs (32.02, IC95% 9.45-64.59) suggesting that both vaccination treatments succeeded in reducing the Leishmania infective burden. Accordingly, an untreated control dog showed lower levels of IFN γ-β, IL-2, IL4 but not IL-10 β actin-relative quantification. We conclude that the VR1012-NH36 vaccine induces strong prophylactic protection and a milder immunotherapeutic effect against a high dose canine experimental infection with Leishmania chagasi.

Schlagwörter

Stichwörter der Autor:innen

Canine visceral leishmaniasisDNA vaccinesImmunotherapyLeishmaniosesNucleoside hydrolaseProphylaxis

Autor:innen und Institutionen

  • Inst. de Microbiologia Prof. Paulo de Góes., Avenida Carlos Chagas Filho, 373, Cidade Universitária. Ilha do Fundão.Universidade Federal do Rio de Janeiro (UFRJ).Caixa Postal 68040, 21941-902. Rio de Janeiro. BRASIL.
  • Dipartimento di Scienze Cliniche Veterinarie, Università di Napoli Federico II, Via F. Delpino. 1-80137 Napoli, Italy.

Zitieren

APA

Borja-Cabrera, G. P., Santos, F. B., Picillo, E., Gravino, A. E., Manna, L., & Palatnik-de-Sousa, C. B. (2009). Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis. Procedia in Vaccinology. https://doi.org/10.1016/j.provac.2009.07.019

Vancouver

Borja-Cabrera GP, Santos FB, Picillo E, Gravino AE, Manna L, Palatnik-de-Sousa CB. Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis. Procedia in Vaccinology. 2009. doi:10.1016/j.provac.2009.07.019

BibTeX
@article{BorjaCabrera2009,
  author = {Borja-Cabrera, G P and Santos, F B and Picillo, E and Gravino, A E and Manna, L and Palatnik-de-Sousa, C B},
  title = {Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis},
  journal = {Procedia in Vaccinology},
  year = {2009},
  doi = {10.1016/j.provac.2009.07.019}
}
Kostenlos starten →